(RTTNews) - Swiss drug major Novartis AG (NVS, NOVN.SW) Thursday announced its mid-term guidance to 2026-2031, with net sales expected to grow 5 percent at constant currency CAGR. The firm added that core operating income margin is on track to return to more than 40 percent by 20
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.
